Paper29348681
Impact of a five-dimensional framework on R&D productivity at AstraZeneca.
Morgan P and 16 others. Nat Rev Drug Discov, 2018. Cited by 294 papers, by iCite.
Cite this record
ConductScience Library. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Papers, record 29348681. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29348681
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biomedical Research | Major topic |
| Decision Making, Organizational | Major topic |
| Drug Industry | Major topic |
| Drugs, Investigational | Major topic |
| Efficiency, Organizational | Major topic |
| Research | Major topic |
| Research Design | Major topic |
| Clinical Trials as Topic | |
| Efficiency | |
| Humans | |
| Organizational Culture |
Source PubMed
References120
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25336761 | Existing and Emerging Technologies for Point-of-Care Testing. | Clin Biochem Rev | 2014 | https://conductscience.org/library/papers/25336761 | PubMed |
| 2 | 26457449 | How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets. | J Med Chem | 2016 | https://conductscience.org/library/papers/26457449 | PubMed |
| 3 | 27932801 | DNA-encoded chemistry: enabling the deeper sampling of chemical space. | Nat Rev Drug Discov | 2017 | https://conductscience.org/library/papers/27932801 | PubMed |
| 4 | 23449292 | European lead factory opens for business. | Nat Rev Drug Discov | 2013 | https://conductscience.org/library/papers/23449292 | PubMed |
| 5 | 27417848 | Reducing the risk of failure: biomarker-guided trial design. | Nat Rev Drug Discov | 2016 | https://conductscience.org/library/papers/27417848 | PubMed |
| 6 | 24448973 | Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. | Cochrane Database Syst Rev | 2014 | https://conductscience.org/library/papers/24448973 | PubMed |
| 7 | 25628072 | Factors influencing quality decision-making: regulatory and pharmaceutical industry perspectives. | Pharmacoepidemiol Drug Saf | 2015 | https://conductscience.org/library/papers/25628072 | PubMed |
| 8 | 21956170 | Workflow and metrics for image quality control in large-scale high-content screens. | J Biomol Screen | 2012 | https://conductscience.org/library/papers/21956170 | PubMed |
| 9 | 18336218 | Recent advances in high throughput screening for ADME properties. | Comb Chem High Throughput Screen | 2008 | https://conductscience.org/library/papers/18336218 | PubMed |
| 10 | 25306557 | Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. | Lancet Respir Med | 2014 | https://conductscience.org/library/papers/25306557 | PubMed |
| 11 | 24893891 | AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. | Cancer Discov | 2014 | https://conductscience.org/library/papers/24893891 | PubMed |
| 12 | 28244990 | The chemical evolution of oligonucleotide therapies of clinical utility. | Nat Biotechnol | 2017 | https://conductscience.org/library/papers/28244990 | PubMed |
| 13 | 27140035 | Secondary pharmacology: screening and interpretation of off-target activities - focus on translation. | Drug Discov Today | 2016 | https://conductscience.org/library/papers/27140035 | PubMed |
| 14 | 27913228 | PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. | J Thorac Oncol | 2017 | https://conductscience.org/library/papers/27913228 | PubMed |
| 15 | 11927654 | IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. | J Leukoc Biol | 2002 | https://conductscience.org/library/papers/11927654 | PubMed |
| 16 | 27177493 | Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. | Lancet Respir Med | 2016 | https://conductscience.org/library/papers/27177493 | PubMed |
| 17 | 23400000 | Development of PI3K inhibitors: lessons learned from early clinical trials. | Nat Rev Clin Oncol | 2013 | https://conductscience.org/library/papers/23400000 | PubMed |
| 18 | 27435396 | Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/27435396 | PubMed |
| 19 | 27469033 | Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. | Nat Rev Drug Discov | 2016 | https://conductscience.org/library/papers/27469033 | PubMed |
| 20 | 22697420 | The right compound in the right assay at the right time: an integrated discovery DMPK strategy. | Drug Metab Rev | 2012 | https://conductscience.org/library/papers/22697420 | PubMed |
Cited by149
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 294 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42943207 | Clinically Anchored GPCR Drug Discovery: Translational Lessons from Success, Failure, and Post-Approval Reassessment. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42943207 | PubMed |
| 42866684 | Persistent clinical attrition does not establish animal models as a root cause of drug-development failures. | NAM J | 2026 | https://conductscience.org/library/papers/42866684 | PubMed |
| 42855516 | Proteome-guided drug discovery maps and mitigates therapeutic degrader toxicity. | Nat Chem Biol | 2026 | https://conductscience.org/library/papers/42855516 | PubMed |
| 42835622 | Six decades of evidence: biological factors predominate among reported reasons for clinical drug failure: A response to "Persistent clinical attrition does not establish animal models as a root cause of drug-development failures" by Peter MA Groenen. | NAM J | 2026 | https://conductscience.org/library/papers/42835622 | PubMed |
| 42785112 | Evoke (+) trials of semaglutide for early alzheimer's disease: Innovations, lessons, and implications. | J Prev Alzheimers Dis | 2026 | https://conductscience.org/library/papers/42785112 | PubMed |
| 42761162 | Integration of microphysiological systems with computational and digital twin modeling for pharmaceutical development: a systematic review. | J Pharm Pharm Sci | 2026 | https://conductscience.org/library/papers/42761162 | PubMed |
| 42702743 | The Governance Gap: Democratizing Drug Development Through Decision Architecture. | Clin Pharmacol Ther | 2026 | https://conductscience.org/library/papers/42702743 | PubMed |
| 42665646 | Data-centric feedback loops for next-generation immunotherapy development. | Nat Biomed Eng | 2026 | https://conductscience.org/library/papers/42665646 | PubMed |
| 42630996 | Epidermal Growth Factor Receptor as a Model Drug Target for Scrutinizing the Status Quo in Drug Discovery and Chemical Biology. | ACS Bio Med Chem Au | 2026 | https://conductscience.org/library/papers/42630996 | PubMed |
| 42576973 | Need for NAMs: A systematic evidence synthesis revealing over half a century of drug development failure. | NAM J | 2026 | https://conductscience.org/library/papers/42576973 | PubMed |
| 42567977 | Artificial intelligence in drug discovery - what it is, where we stand and the path forward. | Nat Rev Drug Discov | 2026 | https://conductscience.org/library/papers/42567977 | PubMed |
| 42443933 | Translational assessment instruments for preclinical to first-in-human decision-making: a scoping review. | J Transl Med | 2026 | https://conductscience.org/library/papers/42443933 | PubMed |
| 42125195 | 25 years of applying the 3Rs principles in safety pharmacology: success stories and future perspectives. | Front Physiol | 2026 | https://conductscience.org/library/papers/42125195 | PubMed |
| 42092189 | A network medicine framework for multi-modal data integration in therapeutic target discovery. | Commun Chem | 2026 | https://conductscience.org/library/papers/42092189 | PubMed |
| 42091774 | De-risking Biopharma Asset Acquisition: Towards a Quantitative Framework for Strategic Decision-making. | AAPS J | 2026 | https://conductscience.org/library/papers/42091774 | PubMed |
| 42023479 | Machine Learning Meets Pharmacokinetics: A Comparative Analysis of Predictive Models for Plasma Concentration-Time Profiles. | CPT Pharmacometrics Syst Pharmacol | 2026 | https://conductscience.org/library/papers/42023479 | PubMed |
| 41977224 | Mapping the Extended Pain Pathway: Human Genetic and Multi-Omic Strategies for Next-Generation Analgesics. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41977224 | PubMed |
| 41970855 | Pharmacokinetic Prediction of Repurposed Drugs for PDAC Using Artificial Intelligence. | ACS Omega | 2026 | https://conductscience.org/library/papers/41970855 | PubMed |
| 41968138 | Advancing target discovery through disease-specific integration of multi-modal target identification models and comprehensive benchmarking system. | Sci Rep | 2026 | https://conductscience.org/library/papers/41968138 | PubMed |
| 41938843 | Zegocractin for acute pancreatitis with systemic inflammatory response syndrome: a randomized, controlled, dose-ranging, phase 2b trial. | EClinicalMedicine | 2026 | https://conductscience.org/library/papers/41938843 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29348681
GET https://conductscience.org/api/papers/v1/29348681/references?page=2